POPULARITY
20 episodes with greg riely
21 episodes with greg riely
2 episodes with greg riely
2 episodes with greg riely
22 - MENS ISSUES WITH INTIMACY - THE HARDER SHAFT PODCAST with Joe-y Busuttil & Greg RielyMen may also experience difficulties achieving intimacy because of a lack of 'emotional vocabulary'. Men often feel less able to express the way they are feeling than women, and may feel uncomfortable with discussions about emotions. However, it is important to remember it is a skill, and as such can be learned.It is common that when someone is experiencing a disturbance in their emotional and mental health, they may not demonstrate as much affection as they would at other times. Some mental health examples include depression, anxiety, post-traumatic stress disorder, or even obsessive compulsive disorder.Many factors can contribute to men's decreased interest in sex. In my own research, the three most commonly endorsed issues that men described as decreasing their desire were sexual rejection, lack of emotional connection with their partners, and physical ailments or health issues.Men who express their emotions are often seen as weak. Because of that, many men neglect to show their emotions because they're afraid of the repercussions. However, suppressing emotions and feelings can be incredibly detrimental to a man's mental health.GREG RILEY:https://www.gregriley.com.au/Facebook [Greg Rileyhttps://www.facebook.com › ... › Mental Health ServiceLinkedInhttps://au.linkedin.com › greg-riley-518b2417Greg Rileyhttps://www.instagram.com › gregriley5dimensions-------------------------------------------------------------------------JOE BUSUTTILMENS COACH/ COUNSELLORthesecretmensbusiness@gmail.comwww.equator-hypnotherapymelbourne.comINSTAGRAM:@the_shaft_experienceFACEBOOK:THE SHAFT EXPERIENCE-SEXUAL HEALTHwww.facebook.com/groups/secretmensbusiness01/the HARDER SHAFT podcast:https://www.podomatic.com/podcasts/thesecretmensbusinessAvailable on all PODCAST PLATFORMS-iTunesSpotifyDeezerGoogle ManagerAmazom MusicPodomaticYOUTUBE:THE SHAFT EXPERIENCE - MENS SEXUAL HEALTHhttps://www.youtube.com/c/TheSHAFTExperienceMENSSexualHealthsuppor
The latest episode of Lung Cancer Considered is a post- AACR debrief focusing on MET testing, TERAVOLT data and life in NYC during COVID-19. This episode features a conversation between host Dr. Jack West and Dr. Greg Riely, vice chair of clinical research in the department of medicine at Memorial Sloan Kettering Cancer Center in New York.
Dr. Greg Riely from MSKCC and Dr. Jack West review the changing role for plasma NGS and local ablation therapy (LAT) for oligometastic disease (OMD) or oligoprogressing advanced NSCLC in clinical practice.
Dr. Greg Riely from MSKCC and Dr. Jack West review the changing role for plasma NGS and local ablation therapy (LAT) for oligometastic disease (OMD) or oligoprogressing advanced NSCLC in clinical practice.
Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center (MSKCC) chats with Dr. Jack West about current standards in molecular testing for advanced NSCLC & potential challenges in execution in translating the promise of genomics into broad practice.
Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center (MSKCC) chats with Dr. Jack West about current standards in molecular testing for advanced NSCLC & potential challenges in execution in translating the promise of genomics into broad practice.
Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.
Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.
Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.
Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center reviews the limited data that help clarify the probability of benefit from new immunotherapy agents among patients with advanced NSCLC and an identified driver mutation.
Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center reviews the limited data that help clarify the probability of benefit from new immunotherapy agents among patients with advanced NSCLC and an identified driver mutation.
Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center reviews the limited data that help clarify the probability of benefit from new immunotherapy agents among patients with advanced NSCLC and an identified driver mutation.
MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung cancer.
MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung cancer.
MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung cancer.
Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.
Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.
Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.
MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.
MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.
MSKCC medical oncologist Dr. Greg Riely explains the growing value of a repeat biopsy after the development of acquired resistance in patients with an EGFR mutation.
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.
Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.
Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.
Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.
Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.
Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.
Memorial Sloan-Kettering Cancer Center medical oncologist Dr. Greg Riely explains how testing for specific mutations in patients with advanced NSCLC can guide prognosis and treatment recommendations.
Memorial Sloan-Kettering Cancer Center medical oncologist Dr. Greg Riely explains how testing for specific mutations in patients with advanced NSCLC can guide prognosis and treatment recommendations.
Memorial Sloan-Kettering Cancer Center medical oncologist Dr. Greg Riely explains how testing for specific mutations in patients with advanced NSCLC can guide prognosis and treatment recommendations.
Dr. Greg Riely, from Memorial Sloan-Kettering, describes which patients with advanced NSCLC he seeks molecular marker testing on, and the particular markers he prioritizes.
Dr. Greg Riely, from Memorial Sloan-Kettering, describes which patients with advanced NSCLC he seeks molecular marker testing on, and the particular markers he prioritizes.
Dr. Greg Riely, from Memorial Sloan-Kettering, describes which patients with advanced NSCLC he seeks molecular marker testing on, and the particular markers he prioritizes.
Dr. Greg Riely, from Memorial Sloan-Kettering, gives her view on more widespread availability of new mutation tests.
Dr. Greg Riely, from Memorial Sloan-Kettering, gives her view on more widespread availability of new mutation tests.
Dr. Greg Riely, from Memorial Sloan-Kettering, gives her view on more widespread availability of new mutation tests.
Dr. Greg Riely, from Memorial Sloan-Kettering, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
Dr. Greg Riely, from Memorial Sloan-Kettering, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
Dr. Greg Riely, from Memorial Sloan-Kettering, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.
Dr. Greg Riely, from Memorial Sloan-Kettering, expresses his practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
Dr. Greg Riely, from Memorial Sloan-Kettering, expresses his practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
Dr. Greg Riely, from Memorial Sloan-Kettering, expresses his practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.
Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the evidence and his personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.
Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the evidence and his personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.
Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the evidence and his personal interpretation and recommended approach to maintenance therapy for advanced non-small cell lung cancer.
Dr. Greg Riely, from Memorial Sloan-Kettering, reviews his thought process in recommending a repeat biopsy at initial diagnosis or after progression for patients with advanced lung cancer.
Dr. Greg Riely, from Memorial Sloan-Kettering, reviews his thought process in recommending a repeat biopsy at initial diagnosis or after progression for patients with advanced lung cancer.
Dr. Greg Riely, from Memorial Sloan-Kettering, reviews his thought process in recommending a repeat biopsy at initial diagnosis or after progression for patients with advanced lung cancer.
Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the concept of multiplex next generation sequencing and how it could change molecular oncology.
Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the concept of multiplex next generation sequencing and how it could change molecular oncology.
Dr. Greg Riely, from Memorial Sloan-Kettering, discusses the concept of multiplex next generation sequencing and how it could change molecular oncology.
Dr. Greg Riely offers his view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
Dr. Greg Riely offers his view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
Dr. Greg Riely offers his view on the best way to approach the common scenario of an EGFR mutation or other "driver mutation" being identified after a patient is already on first line chemotherapy. When should we switch from one treatment to another?
Dr. Greg Riely, Memorial Sloan-Kettering, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.
Dr. Greg Riely, Memorial Sloan-Kettering, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.
Dr. Greg Riely, Memorial Sloan-Kettering, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.
Dr. Greg Riely from Memorial Sloan-Kettering notes how he feels molecular marker results for patients with earlier stage lung cancer can potentially be valuable.
Dr. Greg Riely from Memorial Sloan-Kettering notes how he feels molecular marker results for patients with earlier stage lung cancer can potentially be valuable.
Dr. Greg Riely from Memorial Sloan-Kettering notes how he feels molecular marker results for patients with earlier stage lung cancer can potentially be valuable.
Dr. Greg Riely from Memorial Sloan-Kettering reviews strategies for managing acquired resistance to EGFR inhibitors and other targeted therapies in advanced non-small cell lung cancer.
Dr. Greg Riely from Memorial Sloan-Kettering reviews strategies for managing acquired resistance to EGFR inhibitors and other targeted therapies in advanced non-small cell lung cancer.
Dr. Greg Riely from Memorial Sloan-Kettering reviews strategies for managing acquired resistance to EGFR inhibitors and other targeted therapies in advanced non-small cell lung cancer.
Case discussion with Dr. Julie Brahmer of Johns Hopkins University and Dr. Gregory Riely of Memorial Sloan Kettering, on a case of a woman with poorly differentiated NSCLC, responding well to fist line chemotherapy.
Case discussion with Dr. Julie Brahmer of Johns Hopkins University and Dr. Gregory Riely of Memorial Sloan Kettering, on a case of a woman with poorly differentiated NSCLC, responding well to fist line chemotherapy.
© 2020-2025 Ivy Podcast Discovery LLC
